OncoPrecision
- Biotech or pharma, therapeutic R&D
OncoPrecision is a platform therapeutics company integrating patient-derived high-throughput biology with AI/ML to develop a pipeline of ADCs and bispecific antibodies with high PoS–primarily focused on oncology.
Our lead program features a highly selective first-in-class CD64-ADC leveraging a broad monocyte-depletion MoA, which has demonstrated remarkable efficacy and tolerability across multiple in vivo models. This approach has potential applications in both hematology/oncology and solid tumors.